Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1634
This examiner grants 57% of resolved cases
Anne Marie Sabrina Wehbe is an examiner in Tech Center 1600, specifically Art Unit 1631. Her historical data includes 703 resolved cases. The allowance rate for Webe is 57.2 percent, which indicates a balanced prosecution environment. This rate suggests that more than half of the applications result in a patent grant, providing a moderate expectation of success.
The interview lift for Webe is 43.4 percent. This is a very high lift, indicating that interviews are an exceptionally effective tool for increasing the probability of allowance. Practitioners should note that while the baseline rate is 57.2 percent, the 43.4 percent lift suggests that direct verbal communication can significantly change the trajectory of an application toward a successful outcome. Scheduling an interview should be a primary tactical consideration.
The median days to allowance is 1336. This figure represents the typical time required to reach a successful resolution. The 1336-day median, combined with the 57.2 percent allowance rate, suggests that prosecution can be a lengthy process in Art Unit 1631. However, the high 43.4 percent interview lift provides a clear strategy for practitioners looking to improve their chances of success within the 703 resolved cases analyzed.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19570016 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | Final Rejection | Juno Therapeutics, Inc. |
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 17740040 | High-Throughput Identification of Patient-Specific Neoepitopes as Therapeutic Targets for Cancer Immunotherapies | Non-Final OA | Nant Holdings IP, LLC |
| 18351246 | Macrophage Cell Therapy to Treat Orthopedic Injury | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17540968 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | President and Fellows of Harvard College |
| 17579185 | RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18516366 | PROTEIN PROSTHESES FOR MITOCHONDRIAL DISEASES OR CONDITIONS | Final Rejection | The General Hospital Corporation |
| 16639474 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 18893356 | Genetically Modified Non-Human Animals And Methods Of Use Thereof | Non-Final OA | Institute for Research in Biomedicine (IRB) |
| 18464173 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | Final Rejection | Merus N.V. |
| 18460482 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | Final Rejection | Merus N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy